SBIR/STTR Research Award

Development of Small Molecules that Enhance the Delivery and the Pharmacological Effects of Oligonucleotides

Award identifier 91f310abad25242e66da8d838b3ff7697de52beae0209d1487832096a415821aAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$312,031

Program and phase

STTR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Initos Pharmaceuticals LLC
Proposal award date
2015-08-15
Contract end date
2016-08-14
UEI
KSNRWVQ97YN6
Solicitation number
PA14-308
Topic code
999

Research abstract

DESCRIPTION provided by applicant Antisense and siRNA oligonucleotides offer the promise of highly precise manipulation of genes involved in disease pathogenesis However despite the investment of enormous resources that promise has been fulfilled to only a limited degree A key impediment to oligonucleotide based therapeutics is the difficulty in delivering these large highly polar molecules to their sites of action in the cytosol or nucleus of tissue cells While chemical modification of oligonucleotides and the utilization of various nanotechnology based delivery approaches have been helpful the delivery problem remains challenging Much of the oligonucleotide accumulated by cells remains non productively entrapped in endosomes The complex pathways of endocytosis and intracellular trafficking are being increasingly understood at the molecular level however there is a paucity of small molecule probes for these pathways Here we describe a novel technology based on the use of small organic molecules to enhance the functional delivery and pharmacological effectiveness of oligonucleotides by manipulating their intracellular trafficking We have established a proof of principle for this strategy by identifying compounds using a high throughout screen of andgt small molecules Three distinct compound series were discovered from this screen that significantly enhance oligonucleotide effects in cell culture and in one case in a transgenic mouse model We now propose medicinal chemistry efforts to build structure activity relationships and improve both potency and pharmacological properties with the end goal of creating molecules that can effectively and safely be used in vivo Promising leads will be examined for their pharmacokinetic and biodistribution behavior Finally these leads will be evaluated in a xenograft tumor model The identification of potent and non toxic enhancing molecules will likely have a major impact on the entire field of oligonucleotide therapeutics PUBLIC HEALTH RELEVANCE A key impediment to oligonucleotide based therapeutics is the difficulty in delivering these large highly polar molecules to their sites of action in the cyosol or nucleus of tissue cells While chemical modification of oligonucleotides and the utilization of various nanotechnology based delivery approaches have been helpful the delivery problem remains largely unresolved We have taken an orthogonal approach to this problem and have developed small molecule compounds that enhance the functional delivery and pharmacological effectiveness of oligonucleotides by manipulating their intracellular trafficking Here we propose to optimize compounds as in vivo probes it seems likely that this effort will have a major impact on the entire field of oligonucleotide therapeutics

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

3 SBIR/STTR records share this UEI (2015–2020). Reported award amounts total $2,263,916. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.